Italia markets closed

Agios Pharmaceuticals, Inc. (0HB0.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
29,57-1,07 (-3,51%)
Alla chiusura: 05:28PM BST
Schermo intero
Chiusura precedente30,64
Aperto30,50
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno29,57 - 30,50
Intervallo di 52 settimane20,13 - 35,35
Volume10
Media Volume522
Capitalizzazione13,443M
Beta (5 anni mensile)0,86
Rapporto PE (ttm)N/D
EPS (ttm)-6,43
Prossima data utili02 mag 2024 - 06 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Agios to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2023

    CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, 2023, at 7:30 a.m. EST. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com.

  • GlobeNewswire

    Agios Reports Business Highlights and Second Quarter 2023 Financial Results

    Announced Positive Results from Phase 2 Portion of the RISE UP Pivotal Study of Mitapivat in Sickle Cell Disease; On Track to Enroll First Patient in Phase 3 Portion of the Study in Q4 2023 Completed Enrollment in Phase 3 ENERGIZE and ENERGIZE-T Studies of Mitapivat in Thalassemia and Phase 2a Study of AG-946 in Lower-Risk MDSAnnounced Exclusive Worldwide License Agreement with Alnylam Pharmaceuticals to License Alnylam’s Novel siRNA for the Potential Treatment of Polycythemia VeraU.S. PYRUKYND®

  • GlobeNewswire

    Agios Announces Exclusive Worldwide License Agreement for Novel siRNA for the Potential Treatment of Polycythemia Vera

    – Preclinical siRNA Targeting TMPRSS6 is a Potential Disease-Modifying Treatment for Polycythemia Vera – – Agreement Combines Agios’ Scientific Expertise and Capabilities in Rare Hematologic Diseases with Alnylam’s Industry-Leading siRNA Platform – – Alnylam to Receive a $17.5 million Upfront Payment and is Eligible to Receive Potential Future Development and Commercial Milestone Payments and Royalties – CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGI